분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-04-12 00:03:00 , Hit : 1600
 Bristol-Myers hepatitis C treatment cures up to 90 pct -study



By Bill Berkrot

April 10  Thu Apr 10, 2014 7:00am EDT


(Reuters) - A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol's daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease.

The cure rate was also 82 percent among patients unable to tolerate treatment with the older standard drugs interferon and ribavirin and 84 percent in patients who had cirrhosis, which accounted for nearly a third of those in the trial.

Patients for whom the virus was undetectable in the blood 12 weeks after completing 24 weeks of treatment were deemed to have achieved sustained virologic response (SVR), which is considered cured.

"Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease," Professor Michael Manns, the study's lead investigator from Hannover Medical School in Germany, said in a statement.

The study results were presented at the annual meeting of the European Association for the Study of the Liver (EASL) in London.

Genotype 1 is the most prevalent and considered the most difficult to treat form of the virus. Genotype 1b tends to be more common in Europe and 1a is more widely seen in the United States.

Several drugmakers, including Gilead Sciences Inc, AbbVie and Merck & Co are developing a new generation of all-oral hepatitis C treatments that do not include interferon or ribavirin, which cause miserable side effects that have led thousands of patients to put off treatment to wait for the highly touted new drugs.

In clinical trials, the new drugs have demonstrated cure rates in excess of 90 percent while cutting treatment duration to 12 weeks with few side effects, leading to Wall Street forecasts of multibillion-dollar annual sales in what is shaping up to be a fiercely competitive market.

Prior to the recent approval of the first of Gilead's new drugs, standard treatments cured about 75 percent of patients and required either 24 or 48 weeks of therapy.

Bristol this week applied for U.S. approval of the two drug combination and said it expects to file for approval of a three-drug combination early next year.

Based on earlier studies, Bristol's three-drug combination is likely to further boost cure rates with 12 weeks of treatment, which would be more competitive to results seen so far from rival drugmakers.

Patients in the Hallmark-Dual trial received 60 mg of daclatasvir once a day and 100 mg of asunaprevir twice daily. The drugs belong to new classes of medicines that work in different ways to prevent the virus from replicating.

The discontinuation rate due to adverse side effects was between 1 and 3 percent, the company said. Headache was the most common side effect, and serious side effects, such as elevations in liver enzymes, were seen in 5 percent to 7 percent of patients.

Liver enzyme elevations were reversible and resolved following treatment, the company said.

About 170 million people are believed to be infected with hepatitis C worldwide. If left untreated the disease can lead to cirrhosis, liver cancer or need for a liver transplant. (Reporting by Bill Berkrot; Editing by Cynthia Osterman)







867   실험쥐가 남성 연구자로부터 받는 스트레스?  이성욱 2014/05/02 2126
866   세계의 과학자들, 성인의 세포를 이용해 배아줄기세포를 만드는 데 잇달아 성공  이성욱 2014/04/30 1573
865   백신 개발을 위한 HIV의 취약 부위의 발견  이성욱 2014/04/30 1629
864   다운 증후군과 백혈병 사이의 연관성을 밝혀주는 연구 결과  이성욱 2014/04/24 2098
863   다시 뛰는 RNAi: 10억 달러 들여 신약 개발, 150가지 요법 임상시험  이성욱 2014/04/24 2791
862   Anti-viral regimen to treat adults with HCV awaits FDA approval  이성욱 2014/04/24 1437
861   Tales of Aptamer Selection: Astute Observation and Thoughtful Experimentation or Serendipity?  이성욱 2014/04/23 2497
860   암 줄기세포의 항암제 저항성과의 연관성  이성욱 2014/04/23 2313
859   CTLA-4 항체의 항암 효과를 높이는 새로운 혼합치료  이성욱 2014/04/21 2102
858   난자와 정자의 결합을 가능하게 하는 단백질 발견  이성욱 2014/04/21 2067
857   HPV가 만든 인간 유전체의 고리가 암으로 진행  이성욱 2014/04/21 1906
856   First Patent Issued on CRISPR-Cas9  이성욱 2014/04/18 2005
855   왜 여성은 남성보다 더 알츠하이머 질환에 취약한가?  이성욱 2014/04/16 1897
854   트라우마의 추억 - 트라우마의 표지를 운반하는 정자의 miRNA  이성욱 2014/04/16 1921
  Bristol-Myers hepatitis C treatment cures up to 90 pct -study  이성욱 2014/04/12 1600
852   Celladon Gets FDA’s “Breakthrough Therapy” Status for Gene Therapy  이성욱 2014/04/11 1820
851   나쁜 환경의 스트레스가 텔로미어 길이 단축할까  이성욱 2014/04/11 2284
850   FDA grants priority review for ledipasvir/sofosbuvir  이성욱 2014/04/10 1916
849   일본 STAP 세포연구의 세포주 불일치 발견과 조사위원회의 과학적 위법행위 발표  이성욱 2014/04/03 2017
848   STAP 논문, 결국 62일 만에...  이성욱 2014/04/02 1658

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN